MAPT and tauopathy: Notably, QC-01–175 preferentially degraded tau species in patient-derived neurons, while sparing tau in healthy controls, providing a potential therapeutic approach in neutralizing the neurotoxic effects of tau in tauopathies such as FTLD-tau (Silva et al., 2019).